Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., filed a Form 4 on November 19, 2026, reporting the exercise of a stock option and the sale of common stock on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Collins exercised a stock option for 5,000 shares of common stock at an exercise price of $2.48 per share on November 17, 2026.
  • First sale: 4,939 shares were disposed of at a weighted average price of $46.8313, with individual trades ranging from $46.455 to $47.435.
  • Second sale: 61 shares were disposed of at a weighted average price of $47.5954, with individual trades ranging from $47.5074 to $47.745.
  • Remaining holdings: Following all reported transactions, Collins directly held 25,000 shares of common stock, described as RSUs, and 96,268 stock options.
  • 10b5-1 plan: According to the filing, the option exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Collins on October 19, 2025.
  • Option status: The filing states that all 5,000 shares subject to the exercised option were fully vested and exercisable as of the transaction date, with an expiration date of June 17, 2031.

Collins Option Exercise and Share Sales at Enliven Therapeutics on November 17, 2026

According to the Form 4 filed with the SEC on November 19, 2026, Helen Louise Collins, identified as Chief Medical Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), reported three transactions in the company's common stock on November 17, 2026. All transactions were carried out under a Rule 10b5-1 trading plan that Collins adopted on October 19, 2025, as noted in the filing's explanation of responses.

The first transaction was an option exercise coded "M," in which Collins acquired 5,000 shares at the exercise price of $2.48 per share. The underlying stock option carried an expiration date of June 17, 2031, and the filing states that all shares subject to the option were fully vested and exercisable as of the date of the transaction. Following this acquisition, Collins's direct beneficial ownership stood at 30,000 shares, a portion of which the filing describes as restricted stock units (RSUs), each representing a contingent right to receive one share of common stock subject to applicable vesting schedules and conditions.

Collins then disposed of 4,939 shares in a sale coded "S" at a weighted average price of $46.8313, with individual trades executed at prices ranging from $46.455 to $47.435. A second sale of 61 shares followed, also coded "S," at a weighted average price of $47.5954, with trades ranging from $47.5074 to $47.745. After both sales, Collins's direct beneficial ownership in common stock was reported as 25,000 shares, all described as RSUs. The filing also reflects that Collins retains 96,268 stock options following the reported transactions.

What Was Disclosed

The filing reports a stock option exercise of 5,000 shares and two subsequent sales totaling 5,000 shares by Enliven Therapeutics Chief Medical Officer Helen Louise Collins on November 17, 2026, all conducted under a pre-established Rule 10b5-1 trading plan.